Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Portable Test Detects SARS-CoV-2 Antibodies in People Who Have Tested Positive for COVID-19

By LabMedica International staff writers
Posted on 31 Mar 2021
A new easy-to-produce test quickly detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.

An international research team led by scientists at the University of Oxford (Oxford, UK) has developed a portable test for antibodies that fight the novel coronavirus that causes COVID-19. The test, which spots the presence of virus-fighting antibodies rather than a coronavirus infection, can be adapted to work on blood from a finger prick - making it quick and easy to use. The research team, which includes scientists from Taiwan, India, Thailand and France, as well as UK university and NHS researchers, trialed the test on patients with COVID-19, but now hope to adapt it to identify those who have successfully generated antibodies after a vaccine, versus those who may need a booster.

The scientists also hope that the large-scale use of their tests might help researchers and policy-makers track levels of protective immunity in the community. Antibodies are large proteins that lock onto and help the body’s immune system fight off disease-causing organisms, such as the novel coronavirus that causes COVID-19. Both infection with the virus and vaccines can generate antibodies. There are already several commercial tests, which can detect whether someone has antibodies against the novel coronavirus, but these tests are expensive and usually need a central laboratory to analyze them. This is especially a problem in low-income countries.

The test relies on linking a part of the viral spike protein to the surface of red blood cells. When antibodies to the virus are present they create a clump of red blood cells. This clump is big enough to be seen by eye. The test also does not require any special equipment or take a long time to show the results, and is accurate. It correctly identifies coronavirus spike protein antibodies 90% of the time, with less than a 1% false positive rate. The researchers note that they can be adapted to work using blood from a finger prick sample. They now plan to use this very simple test in future trials to see if it can identify those who are protected against COVID-19 from those who may need a booster vaccination.

“Our test is very cheap to produce, so we are using existing funding from charitable donations to offer 10 million tests for research purposes to countries that cannot support very high-tech solutions,” said study lead Professor Alain Townsend from the MRC Human Immunology Unit at Oxford University.

Related Links:
University of Oxford


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Centrifuge
Hematocrit Centrifuge 7511M4
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.